Failure to thrive adverse event reports that record this term

Kind of term: MedDRA preferred term
Plain meaning: poor growth in a child

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 5,126 adverse event reports that record the MedDRA preferred term Failure to thrive. In plain words, the term means: poor growth in a child. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 179 reports in the 12 months to June 2026 and 265 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,337 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 179 (under 0.1%) record this term. Reports for male patients were 47.6% of the reports that record this term and 34.6% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Plain meaning

Poor growth in a child. The words are from the fixed dictionary of this site. They add nothing to a report.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 143 drug pages with 10 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Failure to thrive name as a suspect product, in order of name
Drug	Class	Reports with this term
Abraxane	Microtubule inhibitor	22
Adalimumab	Tumor necrosis factor blocker	11
Afinitor	Kinase inhibitor	18
Ambrisentan	Endothelin receptor antagonist	20
Anakinra	Interleukin-1 receptor antagonist	13
Aredia		25
Aspirin	Nonsteroidal anti-inflammatory drug	21
Atezolizumab	Programmed death Receptor-1 blocking antibody	18
Avastin	Vascular endothelial growth factor inhibitor	38
Bevacizumab	Vascular endothelial growth factor inhibitor	80
Busulfan	Alkylating drug	12
Cabometyx	Kinase inhibitor	20
Canakinumab		10
Capecitabine	Nucleoside metabolic inhibitor	27
Carboplatin	Platinum-based drug	123
Cetuximab	Epidermal growth factor receptor antagonist	23
Cisplatin	Platinum-based drug	130
Clozapine	Atypical antipsychotic	24
Coreg	alpha-Adrenergic blocker	12
Coumadin		13
Creon		10
Crizotinib	Kinase inhibitor	10
Cyclophosphamide	Alkylating drug	62
Cyclosporine	Calcineurin inhibitor immunosuppressant	24
Cytarabine	Nucleoside metabolic inhibitor	15
Dexamethasone	Corticosteroid	88
Dianeal		195
Dianeal Low Calcium		89
Dianeal Low Calcium Peritoneal Dialysis Solution with Dextrose		93
Diazepam	Benzodiazepine	12
Digoxin	Cardiac glycoside	41
Docetaxel	Microtubule inhibitor	34
Doxil	Anthracycline topoisomerase inhibitor	16
Doxorubicin	Anthracycline topoisomerase inhibitor	48
Doxorubicin hydrochloride	Anthracycline topoisomerase inhibitor	14
Duopa	Aromatic amino acid	10
Eliquis	Factor Xa inhibitor	17
Eloxatin		12
Enzalutamide	Androgen receptor inhibitor	10
Erbitux	Epidermal growth factor receptor antagonist	13
Erlotinib	Kinase inhibitor	31
Erlotinib hydrochloride	Kinase inhibitor	19
Etoposide	Topoisomerase inhibitor	37
Extraneal	Osmotic laxative	57
Fludarabine	Nucleoside metabolic inhibitor	24
Fluorouracil	Nucleoside metabolic inhibitor	62
Forteo	Parathyroid hormone analog	11
Fosamax	Bisphosphonate	23
Gemcitabine	Nucleoside metabolic inhibitor	50
Gemcitabine hydrochloride	Nucleoside metabolic inhibitor	16
Heparin sodium	Anti-coagulant	12
Humira		49
Imbruvica	Kinase inhibitor	23
Infliximab	Tumor necrosis factor blocker	23
Ipilimumab	CTLA-4-directed blocking antibody	26
Irinotecan		18
Jakafi	Janus kinase inhibitor	15
Januvia	Dipeptidyl peptidase 4 inhibitor	27
Keppra		15
Keytruda	Programmed death Receptor-1 blocking antibody	12
Lamivudine	Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	12
Lamotrigine	Anti-epileptic agent	16
Lapine t-lymphocyte immune globulin		10
Lasix	Loop diuretic	12
Lenalidomide	Thalidomide analog	25
Lenvatinib	Kinase inhibitor	11
Leucovorin		15
Leucovorin calcium	Folate analog	26
Levofloxacin	Fluoroquinolone antibacterial	13
Lorazepam	Benzodiazepine	11
Melphalan	Alkylating drug	14
Memantine hydrochloride	N-methyl-D-aspartate receptor antagonist	15
Meropenem	Penem antibacterial	11
Methotrexate	Folate analog metabolic inhibitor	51
Methylprednisolone	Corticosteroid	46
Metoclopramide	Dopamine-2 receptor antagonist	10
Metronidazole	Nitroimidazole antimicrobial	11
Mycophenolate mofetil	Antimetabolite immunosuppressant	73
Mycophenolic acid	Antimetabolite immunosuppressant	13
Nevirapine	Human immunodeficiency virus 1 Non-Nucleoside analog reverse transcriptase inhibitor	15
Nexium	Proton pump inhibitor	13
Nivolumab	Programmed death Receptor-1 blocking antibody	64
Northera		15
Nuplazid	Atypical antipsychotic	80
Nutropin Aq		12
Ofatumumab	CD20-directed cytolytic antibody	11
Omeprazole	Proton pump inhibitor	17
Ondansetron	Serotonin-3 receptor antagonist	39
Ondansetron hydrochloride	Serotonin-3 receptor antagonist	11
Opdivo	Programmed death Receptor-1 blocking antibody	10
Opsumit	Endothelin receptor antagonist	14
Oxaliplatin	Platinum-based drug	62
Oxycodone hydrochloride	Opioid agonist	13
Paclitaxel	Microtubule inhibitor	53
Palbociclib	Kinase inhibitor	10
Pantoprazole sodium	Proton pump inhibitor	11
Paroxetine hydrochloride	Serotonin reuptake inhibitor	11
Paxil	Serotonin reuptake inhibitor	76
Pegasys	Interferon alpha	22
Pembrolizumab	Programmed death Receptor-1 blocking antibody	30
Pemetrexed	Folate analog metabolic inhibitor	11
Pomalyst	Thalidomide analog	36
Potassium chloride	Osmotic laxative	11
Prednisolone	Corticosteroid	22
Prednisone	Corticosteroid	139
Prevacid	Proton pump inhibitor	13
Prilosec	Proton pump inhibitor	16
Prograf	Calcineurin inhibitor immunosuppressant	21
Prolia	RANK ligand inhibitor	16
Remicade	Tumor necrosis factor blocker	24
Remodulin	Prostacycline vasodilator	30
Revlimid	Thalidomide analog	230
Risperdal	Atypical antipsychotic	11
Rituximab	CD20-directed cytolytic antibody	65
Sabril	Anti-epileptic agent	10
Sorafenib	Kinase inhibitor	10
Sutent	Kinase inhibitor	19
Synagis	Respiratory syncytial virus Anti-F protein monoclonal antibody	18
Tacrolimus	Calcineurin inhibitor immunosuppressant	73
Tarceva		10
Taxol		29
Taxotere		12
Temozolomide	Alkylating drug	16
Thalomid		52
Tocilizumab	Interleukin-6 receptor antagonist	10
Topamax		13
Tracleer	Endothelin receptor antagonist	20
Tysabri	Integrin receptor antagonist	22
Valproic acid	Anti-epileptic agent	10
Vedolizumab	Integrin receptor antagonist	12
Velcade	Proteasome inhibitor	43
Venlafaxine hydrochloride	Serotonin and norepinephrine reuptake inhibitor	13
Vincristine		25
Vincristine sulfate	Vinca alkaloid	10
Xarelto	Factor Xa inhibitor	11
Xeloda	Nucleoside metabolic inhibitor	13
Xl184		14
Xtandi	Androgen receptor inhibitor	23
Zidovudine	Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	20
Zofran		86
Zofran Odt		35
Zoloft	Serotonin reuptake inhibitor	54
Zometa		39

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 40 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Failure to thrive name, in order of name
Class	Reports with this term
Alkylating drug	124
Androgen receptor inhibitor	33
Anthracycline topoisomerase inhibitor	78
Anti-epileptic agent	47
Antimetabolite immunosuppressant	91
Atypical antipsychotic	148
Benzodiazepine	26
Bisphosphonate	36
Calcineurin inhibitor immunosuppressant	125
Cardiac glycoside	41
CD20-directed cytolytic antibody	82
Corticosteroid	329
CTLA-4-directed blocking antibody	28
Dipeptidyl peptidase 4 inhibitor	27
Endothelin receptor antagonist	58
Epidermal growth factor receptor antagonist	38
Factor Xa inhibitor	32
Folate analog	28
Folate analog metabolic inhibitor	74
Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	29
Integrin receptor antagonist	34
Janus kinase inhibitor	32
Kinase inhibitor	278
Microtubule inhibitor	109
Nonsteroidal anti-inflammatory drug	27
Nucleoside metabolic inhibitor	221
Opioid agonist	51
Osmotic laxative	82
Platinum-based drug	315
Programmed death Receptor-1 blocking antibody	136
Prostacycline vasodilator	35
Proteasome inhibitor	61
Proton pump inhibitor	103
Serotonin and norepinephrine reuptake inhibitor	28
Serotonin reuptake inhibitor	183
Serotonin-3 receptor antagonist	50
Thalidomide analog	298
Topoisomerase inhibitor	52
Tumor necrosis factor blocker	79
Vascular endothelial growth factor inhibitor	124

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Failure to thrive, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Failure to thrive
Age	Reports	Share
Under 2	269	5.2%
2 to 11	189	3.7%
12 to 17	75	1.5%
18 to 44	161	3.1%
45 to 64	684	13.3%
65 to 74	767	15%
75 and over	916	17.9%
Age not given	2,065	40.3%

Sex of the patient in the reports that record Failure to thrive
Sex	Reports	Share
Female	2,269	44.3%
Male	2,442	47.6%
Unknown or not given	415	8.1%

Age and sex are as the report gives them. 83% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Failure to thrive: adverse event reports that record this term. https://reportedreactions.com/reaction/failure-to-thrive/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Failure to thrive mean in an adverse event report?

In plain words: poor growth in a child. It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page